Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats

Erythropoietin (EPO), well known for its role in stimulation of erythropoiesis, has recently been shown to have a dramatic neuroprotective effect in animal models of cerebral ischemia, mechanical trauma of the nervous system, and excitotoxins, mainly by reducing apoptosis. We studied the effect of single systemic administration of recombinant human EPO (rhEPO) on left ventricular (LV) size and function in rats during 8 weeks after the induction of a myocardial infarction (MI) by permanent ligation of the left descending coronary artery. We found that an i.p. injection of 3,000 units/kg of rhEPO immediately after the coronary artery ligation resulted, 24 h later, in a 50% reduction of apoptosis in the myocardial area at risk. Eight weeks after the induction of MI, rats treated with rhEPO had an infarct size 15–25% of the size of that in untreated animals. The reduction in myocardial damage was accompanied by reductions in LV size and functional decline as measured by repeated echocardiography. Thus, a single dose of rhEPO administered around the time of acute, sustained coronary insufficiency merits consideration with respect to its therapeutic potential to limit the extent of resultant MI and contractile dysfunction.

[1]  B. Rosslenbroich,et al.  A dose-dependent effect of recombinant erythropoietin on the reticulocyte population of rats , 1989, Blut.

[2]  C. Heeschen,et al.  Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. , 2003, Blood.

[3]  R. Kitsis,et al.  A mechanistic role for cardiac myocyte apoptosis in heart failure. , 2003, The Journal of clinical investigation.

[4]  Pietro Ghezzi,et al.  Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[5]  K. Kuck,et al.  Erythropoietin and VEGF exhibit equal angiogenic potential. , 2002, Microvascular research.

[6]  G. Scambia,et al.  Erythropoietin exerts anti‐apoptotic effects on rat microglial cells in vitro , 2002, The European journal of neuroscience.

[7]  C. Grimm,et al.  HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration , 2002, Nature Medicine.

[8]  A. Cerami,et al.  Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[9]  K. Flanders,et al.  Erythropoietin receptor signalling is required for normal brain development. , 2002, Development.

[10]  S. Weiss,et al.  Erythropoietin Regulates the In Vitro and In Vivo Production of Neuronal Progenitors by Mammalian Forebrain Neural Stem Cells , 2001, The Journal of Neuroscience.

[11]  H. Krumholz,et al.  Blood transfusion in elderly patients with acute myocardial infarction. , 2001, The New England journal of medicine.

[12]  P. Lewczuk,et al.  Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[13]  M. Kizaki,et al.  Mcl-1, an early-induction molecule, modulates activin A-induced apoptosis and differentiation of CML cells , 2001, Oncogene.

[14]  W. Brück,et al.  Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain , 2001, Acta Neuropathologica.

[15]  P Ghezzi,et al.  Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[16]  S. Juul,et al.  Nonerythropoietic roles of erythropoietin in the fetus and neonate. , 2000, Clinics in perinatology.

[17]  S. Sawyer,et al.  State-of-the-Art Review: Unraveling Distinct Intracellular Signals That Promote Survival and Proliferation: Study of Erythropoietin, Stem Cell Factor, and Constitutive Signaling in Leukemic Cells , 2000 .

[18]  D. Altavilla,et al.  Recombinant human erythropoietin inhibits iNOS activity and reverts vascular dysfunction in splanchnic artery occlusion shock , 1999, British journal of pharmacology.

[19]  V. Todorov,et al.  Single dose recombinant human erythropoietin reduces transforming growth factor beta in patients on chronic haemodialysis. , 1998, Archives of physiology and biochemistry.

[20]  W. Cheung,et al.  Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects* , 1998, Clinical pharmacology and therapeutics.

[21]  P. Mayeux,et al.  Biology of erythropoietin. , 1998, Haematologica.

[22]  R. Kitsis,et al.  Myocyte apoptosis during acute myocardial infarction in the mouse localizes to hypoxic regions but occurs independently of p53. , 1997, The Journal of clinical investigation.

[23]  Z. Liu,et al.  Tissue specific expression of human erythropoietin receptor in transgenic mice. , 1994, Developmental biology.

[24]  H. Lodish,et al.  Structure, function, and activation of the erythropoietin receptor. , 1993, Blood.

[25]  J. Caro,et al.  Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men , 1990, Clinical pharmacology and therapeutics.

[26]  K. Aoki,et al.  Characterization and biological effects of recombinant human erythropoietin. , 1986, Immunobiology.

[27]  F J Schoen,et al.  Triphenyltetrazolium staining of irreversible ischemic injury following coronary artery occlusion in rats. , 1985, The American journal of pathology.

[28]  M. Pfeffer,et al.  Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. , 1985, Circulation.

[29]  J. Egrie,et al.  Characterization of recombinant monkey and human erythropoietin. , 1985, Progress in clinical and biological research.